{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-017561","form_type":"8-K","ticker":"HOOK","cik":"0001760542","company_name":"HOOKIPA Pharma Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.014890+00:00","generated_at":"2026-06-21T20:47:18.297580+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Hookipa Q3 net loss $18.3M; cash $100.7M; secured Roche deal for KRAS-mutated cancers","bullets":["Net loss $18.3M in Q3 2022 vs $20.0M in Q3 2021; revenue $2.2M (down from $3.9M).","Cash $100.7M as of Sep 30, 2022 (up from $66.9M Dec 2021); excludes $25M Roche upfront and up to $30M Gilead stock purchase.","Entered Roche collaboration for HB-700 (KRAS-mutated cancers) and second candidate; $25M upfront, potential $930M milestones plus royalties.","FDA accepted IND for HB-300 (metastatic castration-resistant prostate cancer); Phase 1 start expected Q1 2023.","Phase 2 HB-200 + pembrolizumab data expected H1 2023; >20 patients dosed, enrollment ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-017561","json":"https://secwatch.observer/filing/0001558370-22-017561.json","markdown":"https://secwatch.observer/filing/0001558370-22-017561.md","text":"https://secwatch.observer/filing/0001558370-22-017561.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1760542/000155837022017561/0001558370-22-017561-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1760542/000155837022017561/hook-20221114x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:47:18.297580+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f91d713715a5595afafc05753665e021837dc4fb","claim":"HOOKIPA Pharma Inc. reported Third Quarter 2022 results: revenue $2.2 million, net income $18.3 million.","evidence_excerpt":"stock that Gilead is required to purchase at the discretion of the Company pursuant to the terms of a stock purchase agreement signed in February 2022 ​ Revenue: Revenue was $2.2 million for the three months ended September 30, 2022, compared to $3.9 million for the three months ended September 30, 2021. The decrease was primarily due to lower cost reimbursements","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1760542/000155837022017561/0001558370-22-017561-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Third Quarter 2022"},{"label":"Revenue","value":"$2.2 million"},{"label":"Net income","value":"$18.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}